drugset / Trial / NCT05061628
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
Non-randomizedSingle-groupSingle-blindTreatment
Summary
This is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safety and tolerability of JS006 as Monotherapy and in combination with toripalimab in patients with advanced tumors who have failed standard therapies or who have no standard therapy. It is planned to enroll 69-176 patients into the study.
Timeline
- Start
- 2021-04-21
- Primary completion
- 2023-04-23
- Completion
- 2023-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS006 | Monoclonal antibody | 18 mg | Intravenous |
| Subject | JS006 | Monoclonal antibody | 60 mg | Intravenous |
| Subject | JS006 | Monoclonal antibody | 180 mg | Intravenous |
| Subject | JS006 | Monoclonal antibody | 600 mg | Intravenous |
| Subject | JS006 | Monoclonal antibody | 1800 mg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |